# US 2023/0265091 A1 · Compounds which inhibit rna polymerase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265091 A1
- Document ID: US20230265091A1
- Status: Published application
- Kind: A1
- Application number: 18/024,407
- Filed: 2021-09-15
- Published: 2023-08-24
- Earliest claimed: 2020-09-15
- Assignees: The Johns Hopkins University; Lieber Institute, Inc.
- Applicants: The Johns Hopkins University; Lieber Institute, Inc.
- Inventors: Hester Hui Liu; James C. Barrow; Marikki K. Laiho; Rajesh Kumar Nv; Pablo de Leon; Tony Dorado; Asma Begum; Wenjun Fan; Gregory Stachelek
- Web page: https://patentgrep.com/patent/US20230265091A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit RNA polymerase I (Pol I). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) Pol I activity contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is H or C1-3 alkyl;
R2 is selected from the group consisting of:
(c) —NR6R7, wherein R6 and R7 are independently selected from the group consisting of: H and C1-6 alkyl which is optionally substituted with from 1-6 Ra; and
(d) -heterocyclyl including from 4-12 ring atoms, wherein from 1-3 ring atoms are ring heteroatoms each independently selected from the group consisting of N, NH, N(Rd), O, and S(O)0-2, wherein the heterocyclyl is optionally substituted with from 1-6 Rb;
L1 is a bond or C1-6 alkylene which is optionally substituted with from 1-6 Rc, provided that when L1 is a bond, then R2 is heterocyclyl that is attached to L1 via a ring carbon atom;
R3a, R3b, R3c, R4a, R4b, R5a, R5b, R5e, and R5d are each independently selected from the group consisting of: H, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and OH;
each occurrence of Ra and Rc is independently selected from the group consisting of: —OH; -halo; —NR′R″; C1-4 alkoxy; C1-4 haloalkoxy; —C(═O)O(C1-4 alkyl); —C(═O)(C1-4 alkyl); —C(═O)OH; —CONR′R″; —S(O)1-2NR′R″; —S(O)1-2(C1-4 alkyl); and cyano;
each occurrence of Rb is independently selected from the group consisting of: C1-6 alkyl optionally substituted with —OH, C1-4 alkoxy, or C1-4 haloalkoxy; C1-6 haloalkyl; oxo; —OH; -halo; —NR′R″; C1-4 alkoxy; C1-4 haloalkoxy; —C(═O)O(C1-4 alkyl); —C(═O)(C1-4 alkyl); —C(═O)OH; —CONR′R″; —S(O)1-2NR′R″; —S(O)1-2(C1-4 alkyl); and cyano;
each occurrence of Rd is independently C1-6 alkyl; —C(O)(C1-4 alkyl); or —C(O)O(C1-4 alkyl); and
each occurrence of R′ and R″ is independently H or C1-3 alkyl,
provided that the compound is other than Compounds 1-39 as delineated in WO 2015/143293.

### Claim 2 (depends on 1)

The compound of claim 1, provided that one or more of (aa), (bb), (cc), and (dd) apply:
(aa) L1 is —CH2— or —CH(C1-3 alkyl)-, each optionally substituted with from 1-3 Rc;
(bb) R2 is heterocyclyl including from 4-12 ring atoms, wherein from 1-3 ring atoms are ring heteroatoms each independently selected from the group consisting of N, NH, N(Rd), O, and S(O)0-2, wherein the heterocyclyl is substituted with 1-6 Rb at one or more ring carbon atoms, provided that at least one Rb is other than oxo;
(cc) R2 is heterocyclyl including from 4-12 ring atoms, wherein from 1-3 ring atoms are ring heteroatoms each independently selected from the group consisting of N, NH, N(Rd), O, and S(O)0-2, wherein the heterocyclyl is optionally substituted with from 1-6 Rb, provided that one ring atom is S(O)0-2; or
(dd) R2 is —NR6R7, wherein R6 is C1-6 alkyl which is substituted with from 1-6 Ra, wherein at least one Ra is other than OMe.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein L1 is C1-6 alkylene optionally substituted with from 1-6 Rc.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein L1 is —CH2— or —CH(C1-3 alkyl)-, each optionally substituted with from 1-3 Rc.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein L1 is unsubstituted —CH2— or —CH(C1-3 alkyl)-, such as —CH2— or —CH(Me)-.

### Claim 6 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein L1 is —CH2CH2— which is optionally substituted with from 1-3 Rc.

### Claim 7 (depends on 1, 2, 3, 6)

The compound of any one of claims 1-3 or 6, wherein L1 is unsubstituted —CH2CH2—.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R2 is heterocyclyl including from 4-12 ring atoms, wherein from 1-3 ring atoms are ring heteroatoms each independently selected from the group consisting of N, NH, N(Rd), O, and S(O)0-2, wherein the heterocyclyl is optionally substituted with from 1-6 Rb.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein R2 is heterocyclyl including from 4-6 ring atoms, wherein from 1-3 ring atoms are ring heteroatoms each independently selected from the group consisting of N, NH, N(Rd), O, and S(O)0-2, wherein the heterocyclyl is substituted with 1-6 Rb at one or more ring carbon atoms, provided that at least one Rb is other than oxo.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, wherein R2 is selected from the group consisting of: pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and thiomorpholinyl, each of which is substituted with from 1-4 (such as 1-2) Rb at one or more ring carbon atoms, provided that at least one Rb is other than oxo, wherein R2 is optionally substituted with Rd at a ring nitrogen atom.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R2 is selected from the group consisting of:

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R2 is heterocyclyl including from 4-6 ring atoms, wherein from 1-3 ring atoms are ring heteroatoms each independently selected from the group consisting of N, NH, N(Rd), O, and S(O)0-2.

### Claim 13 (depends on 12)

The compound of claim 12, wherein R2 is selected from the group consisting of:

### Claim 14 (depends on 12)

The compound of claim 12, wherein R2 includes one ring S(O)0-2 atom, such as wherein R2 is

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The compound of any one of claims 1-14, wherein each Rb is independently selected from the group consisting of: halo (such as —F); cyano; —OH; oxo; C1-3 alkyl optionally substituted with —OH; and C1-3 alkoxy.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 1-15, wherein each Rb is independently selected from the group consisting of: halo (such as —F); cyano; —OH; C1-3 alkyl optionally substituted with —OH; and C1-3 alkoxy.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, wherein Rd is selected from the group consisting of: C1-6 alkyl and C(O)OC1-4 alkyl, such as C1-3 alkyl or C(O)OC1-3 alkyl.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R2 is NR6R7.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 18)

The compound of any one of claims 1-7 or 18, wherein R2 is NR6R7; and R6 is C1-6 alkyl which is substituted with from 1-6 Ra, such as

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, wherein each Ra is independently selected from the group consisting of: halo; cyano; OH; and C1-3 alkoxy, such as halo; cyano; OH; and C2-3 alkoxy.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 18, 19, 20)

The compound of any one of claims 1-7 or 18-20, wherein R7 is unsubstituted C1-3 alkyl, such as methyl.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, wherein R1 is H.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound of any one of claims 1-22, wherein R3a, R3b, R3c, R4a, R4b, R5a, R5b, R5e, and R5d are each H.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound of any one of claims 1-23, wherein the compound is selected from the group consisting of the compounds in Table C1, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A pharmaceutical composition comprising a compound of any of claims 1-24, and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for activating upstream p53 pathways in a mammalian cell, wherein the method comprises contacting a cell or population of cells with a compound as claimed in any one of claims 1-24, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 25.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for modulating RNA Pol I activity in a mammalian cell, wherein the method comprises contacting a cell or population of cells with a compound as claimed in any one of claims 1-24, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 25.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for treating cancer in a subject, wherein the method comprises administering to the subject a compound as claimed in any one of claims 1-24, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 25.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for treating an autoimmune disease or disorder in a subject, wherein the method comprises administering to the subject a compound as claimed in any one of claims 1-24, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 25.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for treating a condition associated with inflammation or pain in a subject, wherein the method comprises administering to the subject a compound as claimed in any one of claims 1-24, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 25.

### Claim 31 (depends on 28, 29, 30)

The method of any one of claims 28-30, further comprising administering to the subject at least one additional therapeutic agent.
